Transcat (TRNS) Competitors $91.63 +1.24 (+1.37%) Closing price 04:00 PM EasternExtended Trading$91.78 +0.15 (+0.16%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRNS vs. TXG, ALNT, LAB, EYPT, SENS, CTKB, QSI, AEHR, QTRX, and MASSShould you be buying Transcat stock or one of its competitors? The main competitors of Transcat include 10x Genomics (TXG), Allient (ALNT), Standard BioTools (LAB), EyePoint Pharmaceuticals (EYPT), Senseonics (SENS), Cytek Biosciences (CTKB), Quantum-Si (QSI), Aehr Test Systems (AEHR), Quanterix (QTRX), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry. Transcat vs. 10x Genomics Allient Standard BioTools EyePoint Pharmaceuticals Senseonics Cytek Biosciences Quantum-Si Aehr Test Systems Quanterix 908 Devices 10x Genomics (NASDAQ:TXG) and Transcat (NASDAQ:TRNS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking, profitability, risk and earnings. Does the MarketBeat Community believe in TXG or TRNS? Transcat received 147 more outperform votes than 10x Genomics when rated by MarketBeat users. Likewise, 66.04% of users gave Transcat an outperform vote while only 50.39% of users gave 10x Genomics an outperform vote. CompanyUnderperformOutperform10x GenomicsOutperform Votes6550.39% Underperform Votes6449.61% TranscatOutperform Votes21266.04% Underperform Votes10933.96% Which has more volatility & risk, TXG or TRNS? 10x Genomics has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500. Comparatively, Transcat has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Do analysts rate TXG or TRNS? 10x Genomics presently has a consensus price target of $15.81, suggesting a potential upside of 92.07%. Transcat has a consensus price target of $114.00, suggesting a potential upside of 27.62%. Given 10x Genomics' higher probable upside, research analysts clearly believe 10x Genomics is more favorable than Transcat.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 8 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.38Transcat 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to TXG or TRNS? In the previous week, Transcat had 2 more articles in the media than 10x Genomics. MarketBeat recorded 12 mentions for Transcat and 10 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 0.90 beat Transcat's score of 0.36 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Transcat 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings and valuation, TXG or TRNS? Transcat has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$624.66M1.61-$182.63M-$1.30-6.33Transcat$278.42M2.99$13.65M$1.5657.26 Do insiders and institutionals believe in TXG or TRNS? 84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 98.3% of Transcat shares are owned by institutional investors. 9.4% of 10x Genomics shares are owned by insiders. Comparatively, 2.3% of Transcat shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is TXG or TRNS more profitable? Transcat has a net margin of 6.22% compared to 10x Genomics' net margin of -29.90%. Transcat's return on equity of 7.23% beat 10x Genomics' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-29.90% -25.40% -19.69% Transcat 6.22%7.23%5.67% SummaryTranscat beats 10x Genomics on 12 of the 18 factors compared between the two stocks. Get Transcat News Delivered to You Automatically Sign up to receive the latest news and ratings for TRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRNS vs. The Competition Export to ExcelMetricTranscatInstruments to measure electricity IndustryComputer SectorNASDAQ ExchangeMarket Cap$832.55M$4.14B$25.10B$8.39BDividend YieldN/A0.46%2.89%4.10%P/E Ratio48.3422.1144.5919.71Price / Sales2.992.372,073.75117.54Price / Cash27.1417.8734.7834.62Price / Book2.963.246.644.50Net Income$13.65M$135.28M$739.99M$248.18M7 Day Performance10.43%-1.10%-0.94%0.23%1 Month Performance6.05%12.05%12.57%12.39%1 Year Performance-37.17%-8.84%52,628.85%7.07% Transcat Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRNSTranscat1.2202 of 5 stars$91.63+1.4%$114.00+24.4%-36.3%$852.98M$278.42M49.53920News CoverageEarnings ReportAnalyst UpgradeAnalyst RevisionTXG10x Genomics4.401 of 5 stars$9.49+8.2%$17.81+87.6%-65.3%$1.16B$624.66M-6.241,240Analyst ForecastALNTAllient2.6271 of 5 stars$29.85+3.8%$31.00+3.9%+6.1%$505.33M$516.06M33.921,950Gap UpLABStandard BioTools2.3385 of 5 stars$1.16+8.4%$2.50+115.5%-59.7%$440.59M$169.69M-1.63620Positive NewsEYPTEyePoint Pharmaceuticals2.4493 of 5 stars$5.85+0.7%$25.29+332.2%-49.4%$402.54M$43.27M-2.93120Analyst RevisionGap UpSENSSenseonics1.887 of 5 stars$0.60-4.0%$2.00+233.3%+6.4%$392.53M$22.47M-4.6290Gap UpCTKBCytek Biosciences2.0451 of 5 stars$3.02+3.4%$5.25+73.8%-58.8%$385.35M$197.05M-37.75500News CoverageGap UpQSIQuantum-Si2.6192 of 5 stars$1.51+19.8%$3.48+130.1%-14.7%$276.54M$3.06M-2.36150News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap UpAEHRAehr Test Systems3.8929 of 5 stars$9.11+7.8%$25.00+174.4%-26.3%$271.21M$61.48M12.1590Positive NewsQTRXQuanterix1.8292 of 5 stars$5.73+8.5%$16.20+182.7%-71.3%$222.26M$135.44M-5.41460Positive NewsAnalyst DowngradeGap UpMASS908 Devices2.8061 of 5 stars$5.73+2.0%$5.33-6.9%-28.2%$204.79M$59.63M-3.2460Positive NewsAnalyst Revision Related Companies and Tools Related Companies TXG Competitors ALNT Competitors LAB Competitors EYPT Competitors SENS Competitors CTKB Competitors QSI Competitors AEHR Competitors QTRX Competitors MASS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRNS) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Transcat, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Transcat With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TRNS Stock Free TRNS Stock Alerts